Skip to main content
. 2020 Jan 29;20:68. doi: 10.1186/s12885-020-6551-y

Table 4.

Therapy-associated toxicity by grade per patient

Event Any grade Grade 3 Grade ≥ 4
Any toxicity n (%)
 Nausea Nausea 11 (34.4) 0 (0) 0 (0)
 Fatigue 16 (50) 1 (3.1) 0 (0)
 Neutropenia 15 (47) 2 (6.3) 10 (31.3)
 Mucositis 6 (18.7) 1 (3.1) 0 (0)
 Alopecia Alopecia 32 (100) 0 (0) 0 (0)
 Vomiting 5 (15.6) 0 (0) 0 (0)
 Anaemia Anaemia 29 (90.6) 7 (21.9) 0 (0)
 Leukopenia Leukopenia 21 (65.6) 10 (31.3) 2 (6.3)
 Constipation 7 (21.9) 0 (0) 0 (0)
 Diarrhea Diarrhea 2 (6.3) 0 (0) 0 (0)
 Decreased appetite Decreased appetite 10 (31.3) 0 (0) 0 (0)
 Abdominal pain 3 (3.4) 1 (3.1) 1 (3.1)
 Pyrexia 3 (9.4) 0 (0) 2 (6.3)
 Musculoskeletal pain 2 (6.3) 0 (0) 0 (0)
 Febrile neutropenia 4 (12.5) 1 (3.1) 2 (6.3)
 Infections and infestations 7 (21.9) 1 (3.1) 3 (9.4)
 Infusion-related reaction 1 (3.1) 0 (0) 0 (0)
 Olaratumab-related toxicitiy 0 (0) 0 (0) 0 (0)
 Toxicity leading to discontinuation 1 (3.1) 0 (0) 1 (3.1)
 Cardiac dysfunction 0 (0) 0 (0) 0 (0)

Toxicity was assessed according to the National Cancer Institute (NCI) criteria v5.0